Limited-stage small cell lung cancer: Current chemoradiotherapy treatment paradigms

Oncologist

Volumn 15, Issue 2, 2010, Pages 187-195

  Stinchcombe, Thomas E ^a   Gore, Elizabeth M ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Combined modality therapy; Lung cancer; Radiation therapy; Review article

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; IRINOTECAN; VANDETANIB;

BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; DRUG CONTRAINDICATION; DRUG EFFICACY; HUMAN; LIMITED STAGE LUNG SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION DOSE; REVIEW; SURVIVAL RATE; TREATMENT RESPONSE;

COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77649125253     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0298     Document Type: Review

References (74)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 2006;24:4539-4544.
3. Gaspar LE, Gay EG, Crawford J et al. Limited-stage small-cell lung cancer (stages I-III): Observations from the National Cancer Data Base. Clin Lung Cancer 2005;6:355-360.
4. Turrisi AT 3rd, Kim K, Blum R et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-271.
5. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973;4:31-42.
6. Shepherd FA, Ginsberg RJ, Haddad R et al. Importance of clinical staging in limited small-cell lung cancer: A valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. J Clin Oncol 1993;11:1592-1597.
7. Albain KS, Crowley JJ, LeBlanc M et al. Determinants of improved outcome in small-cell lung cancer: An analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-1574.
8. Osterlind K, Hansen HH, HansenMet al. Mortality and morbidity in longterm surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer. J Clin Oncol 1986;4:1044-1052.
9. Shepherd FA, Crowley J, Van Houtte P et al. The International Association for the Study of Lung Cancer lung cancer staging project: Proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067-1077.
10. Brink I, Schumacher T, Mix M et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1614-1620.
11. Chin R Jr, McCain TW, Miller AA et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: A preliminary study. Lung Cancer 2002;37:1-6.
12. Kut V, Spies W, Spies S et al. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol 2007;30:45-50.
13. Bradley JD, Dehdashti F, Mintun MA et al. Positron emission tomography in limited-stage small-cell lung cancer: A prospective study. J Clin Oncol 2004;22:3248-3254.
14. Simon GR, Turrisi A; American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 suppl):324S-339S.
15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer v. 2.2009. Available at http://www.nccn.org/ professionals/physician, accessed July 29, 2009.
16. Faivre-Finn C, Lorigan P, West C et al. Thoracic radiation therapy for limited-stage small-cell lung cancer: Unanswered questions. Clin Lung Cancer 2005;7:23-29.
17. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-895.
18. Pignon JP, Arriagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-1624.
19. Pijls-Johannesma MC, De Ruysscher D, Lambin P et al. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 2005;(1):CD004700.
20. Fried DB, Morris DE, Poole C et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004;22:4837-4845.
21. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006;17:543-552.
22. Spiro SG, James LE, RuddRMet al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: A London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol 2006;24:3823-3830.
23. Jeremic B, Shibamoto Y, Acimovic L et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol 1997;15:893-900.
24. Skarlos DV, Samantas E, Briassoulis E et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2001;12:1231-1238.
25. Work E, Nielsen OS, Bentzen SM et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol 1997;15:3030-3037.
26. Gregor A, Drings P, Burghouts J et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: A European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group study. J Clin Oncol 1997;15:2840-2849.
27. Perry MC, Eaton WL, Propert KJ et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987;316:912-918.
28. Perry MC, Herndon JE 3rd, Eaton WL et al. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: An update of Cancer and Leukemia Group B Study 8083. J Clin Oncol 1998;16:2466-2467.
29. Murray N, Coy P, Pater JL et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11:336-344.
30. Takada M, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-3060.
31. De Ruysscher D, Pijls-Johannesma M, Bentzen SM et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006;24:1057-1063.
32. Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J et al. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev 2007;33:461-473.
33. Movsas B, Moughan J, Komaki R et al. Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol 2003;21:4553-4559.
34. Schild SE, Bonner JA, Shanahan TG et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:943-951.
35. Choi NC, Herndon JE 2nd, Rosenman J et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated- accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3528-3536.
36. Bogart JA, Herndon JE 2nd, Lyss AP et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: Analysis of Cancer and Leukemia Group B Study 39808. Int J Radiat Oncol Biol Phys 2004;59:460-468.
37. Komaki R, Swann RS, Ettinger DS et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) Protocol 97-12. Int J Radiat Oncol Biol Phys 2005;62:342-350.
38. Komaki R, Paulus R, Ettinger DS et al. A phase II study of accelerated high-dose thoracic radiation therapy (AHTRT) with concurrent chemotherapy for limited small cell lung cancer: RTOG0239 [abstract 7527]. J Clin Oncol 2009;27(15 suppl):388.
39. ClinicalTrials.gov. Three different radiation therapy regimens in treating patients with limited-stage small cell lung cancer receiving cisplatin and etoposide. Available at http://www.clinicaltrials.gov/ct2/show/NCT00632853, accessed September 9, 2009.
40. ClinicalTrials.gov. Cisplatin, etoposide, and two different schedules of radiation therapy in treating patients with limited-stage small cell lung cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00433563, accessed January 7, 2009.
41. Bunn PA Jr, Nugent JL, Matthews MJ. Central nervous system metastases in small cell bronchogenic carcinoma. Semin Oncol 1978;5:314-322.
42. Gregor A, Cull A, Stephens RJ et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1997;33:1752-1758.
43. Arriagada R, Le Chevalier T, Borie F et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995;87:183-190.
44. Laplanche A, Monnet I, Santos-Miranda JA et al. Controlled clinical trial of prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Lung Cancer 1998;21:193-201.
45. Aroney RS, Aisner J, Wesley MN et al. Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat Rep 1983;67:675-682.
46. Crossen PE, Morrison MJ, Colls BM. Increased frequency of the S allele of the L-myc oncogene in non-Hodgkin's lymphoma. Br J Cancer 1994;69:759-761.
47. Ahles TA, Silberfarb PM, Herndon J 2nd et al. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: A study by the Cancer and Leukemia Group B. J Clin Oncol 1998;16:1954-1960.
48. Komaki R, Meyers CA, Shin DM et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 1995;33:179-182.
49. Arriagada R, Le Chevalier T, Rivière A et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: Analysis of 505 randomized patients. Ann Oncol 2002;13:748-754.
50. Aupérin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476-484.
51. Patel S, Macdonald OK, Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer 2009;115:842-850.
52. Le Péchoux C, Dunant A, Senan S et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): A randomised clinical trial. Lancet Oncol 2009;10:467-474.
53. Baas P, Belderbos JS, Senan S et al. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: A Dutch multicenter phase II study. Br J Cancer 2006;94:625-630.
54. Sunpaweravong P, Magree L, Rabinovitch R et al. A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs 2006;24:213-221.
55. Spigel DR, Hainsworth JD, BurrisHAet al. Long-term follow-up of limited stage small cell lung cancer patients treated with carboplatin-based chemotherapy and radiotherapy by the Minnie Pearl Cancer Research Network (MPCRN) [abstract 7222]. J Clin Oncol 2004;22:671.
56. Levitan N, Dowlati A, Shina D et al. Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol 2000;18:1102-1109.
57. Woo IS, Park YS, Kwon SH et al. A phase II study of VP-16- fosfamidecisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer. Jpn J Clin Oncol 2000;30:542-546.
58. Glisson B, Scott C, Komaki R et al. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: Results of Radiation Therapy Oncology Group Trial 93-12. J Clin Oncol 2000;18:2990-2995.
59. Ettinger DS, Berkey BA, Abrams RA et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: A Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 2005;23:4991-4998.
60. Hanna N, Ansari R, Fisher W et al. Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): A Hoosier Oncology Group (HOG) phase II study. Lung Cancer 2002;35:293-297.
61. Horn L, Bernardo P, Sandler A et al. A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): A trial of the Eastern Cooperative Oncology Group. J Thorac Oncol 2009;4:527-533.
62. Bremnes RM, Sundstrom S, Vilsvik J et al. Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J Clin Oncol 2001;19:3532-3538.
63. Kubota K, Nishiwaki Y, Sugiura T et al. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res 2005;11:5534-5538.
64. Mitsuoka S, Kudoh S, Takada Y et al. Phase II study of cisplatin, etoposide and concurrent thoracic radiotherapy (TRT) followed by irinotecan and cisplatin in patients with limited stage small-cell lung cancer (SCLC); updated results of WJTOG9902 [abstract 7044]. J Clin Oncol 2004;22(14 suppl): 627.
65. Miller AA, Wang XF, Bogart JA et al. Phase II trial of paclitaxel-topotecanetoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J Thorac Oncol 2007;2:645-651.
66. Le QT, Moon J, Redman M et al. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol 2009;27:3014-3019.
67. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
68. Hanna N, Bunn PA Jr, Langer C et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043.
69. Lara PN Jr, Natale R, Crowley J et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-2535.
70. Arnold AM, Seymour L, Smylie M et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007;25:4278-4284.
71. Spigel DR, Hainsworth JD, Yardley DA et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010;28:43-48.
72. Rigas JR, Denham CA, Rinaldi DA et al. Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer [abstract 2525]. Proc Am Soc Clin Oncol 2003;22:628.
73. McClay EF, Bogart J, Herndon JE 2nd et al. A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). Am J Clin Oncol 2005;28:81-90.
74. Lee SM, Woll PJ, Rudd R et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: A randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009;101:1049-1057.